Business
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic equity and non-dilutive alternatives HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that it ha
About this update from Serina Therapeutics, Inc.
[{"type":"image","alt":"Serina Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Serina Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/f5ef3cecb8662785323a6a370007d6d1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vVhesNODR8eRh4qa0Kn9PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f5ef3cecb8662785323a6a370007d6d1","width":300,"height":84}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathway","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Evaluating complementary funding including strategic equity and non-dilutive alternatives ","length":89,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":253,"olType":false},{"type":"text","content":"HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that it has entered into an agreement to access up to $20 million in financing led by Serina Board Director Greg Bailey, MD. The financing also includes the issuance of warrants which, if fully issued and exercised, could result in additional proceeds of up to $20 million.","length":509,"tagName":"p"},{"type":"text","content":"“This financing provides the resources to advance SER-252 through critical clinical milestones on the path toward registration," said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “Importantly, the structure allows us to deploy capital in step with trial progress, while maintaining flexibility to access additional non-dilutive and strategic funding. We believe SER-252 has the potential to transform treatment for those with advanced Parkinson’s disease.”","length":478,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Serina may draw on up to $20 million through an unsecured convertible note to be issued in five tranches, tied to clinical and operational milestones. Key terms of the funding include:","length":218,"tagName":"p"},{"type":"...